Treatment is therefore directed toward relief of symptoms and a reduction in the incidence of acute exacerbations. Within the past decade, major advances in management have been made in the ...
Fixed long-acting combinations of both anticholinergic and beta-agonist bronchodilators, not previously available, have been developed. A new fixed combination of glycopyrronium and indacaterol has ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
Long-Acting Bronchodilators Up Cardiovascular Risk in COPD New use of either long-acting β-agonists or anticholinergics is associated with increased risks of cardiovascular events among older ...
—Long-acting bronchodilators are recommended for initial maintenance of COPD. A new study compares the cardiovascular safety of 2 common treatment options. Reviewed by Ware Kuschner, MD, Professor of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results